

estimated annualized burden is summarized below.

Type of respondents	Number of respondents	Frequency of responses	Average time per response	Annual hour burden
Children (Assessment Instrument Pilot Test) .....	34	1	0.75	25.5
Parents (Assessment Instrument Pilot Test) .....	34	1	1	34.0
Children (Evaluation) .....	120	3	0.5	180.0
Parents (Evaluation: 1 Satisfaction Scale/6 Usage Logs) .....	120	1	0.5	240.0
		6	0.25	
Total .....	308	.....	.....	479.50

### Request for Comments

Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and the assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

### Direct Comments to OMB

Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, room 1-235, Washington, DC 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Cathrine Sasek, Coordinator, Science Education Program, Office of Science Policy and Communications, National Institute on Drug Abuse, 6001 Executive Blvd, Room 5237, Bethesda, MD 20892, or call non-toll-free number (301) 443-

6071; fax (301) 443-6277; or by e-mail to [csasek@nida.nih.gov](mailto:csasek@nida.nih.gov).

### Comments Due Date

Comments regarding this information are best assured of having their full effect if received within 30 days of the date of this publication.

Dated: April 10, 2006.

**Laura Rosenthal,**

*Executive Officer, National Institute on Drug Abuse.*

[FR Doc. 06-3596 Filed 4-13-06; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Public Health Service

### National Institutes of Health

### Submission for OMB Review; Comment Request; National Survey of Primary Care Physicians' Recommendations and Practice for Breast, Cervical, Colorectal, and Lung Cancer Screening

**SUMMARY:** Under the provisions of section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH), National Cancer Institute (NCI), has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below. This proposed information collection was previously published in the **Federal Register** on January 20, 2006, page 3309 and allowed 60-days for public comment. No public comments were received. The purpose of this notice is to allow an additional

30 days for public comment. The National Institutes of Health may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

**Proposed Collection: Title:** National Survey of Primary Care Physicians' Recommendations and Practice for Breast, Cervical, Colorectal, and Lung Cancer Screening. **Type of Information Collection Request:** New. **Need and Use of Information Collection:** This study will obtain current, national data on primary care physicians' knowledge, attitudes, recommendations, and practices related to screening for breast, cervical, colorectal, and lung cancer. There have been substantial changes in guidelines and/or technologies for these types of cancer screening in recent years. The data collected in this study will support and further NCI work in monitoring and evaluating providers' cancer control knowledge, attitudes, and practices and their impact on population health, as well as enable monitoring of progress toward major cancer control goals. Two questionnaires, one covering breast and cervical cancer screening and the other colorectal and lung cancer screening, will be administered by mail or telephone to a randomly-selected national sample of primary care physicians. **Frequency of Response:** One Time. **Affected Public:** Medical practices, clinics, or other health care organizations. **Type of Respondents:** Primary Care Physicians. **Burden estimates** are as follows:

Questionnaire	Estimated number of respondents	Estimated number of responses per respondent	Average burden hours per response	Estimated total annual burden hours
Breast & cervical cancer screening .....	1250	1	0.333	416.25
Colorectal & lung cancer screening .....	1250	1	0.333	416.25
Total .....	.....	.....	.....	832.5

There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

**Request for Comments:** Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (a) Whether the proposed collection of information is necessary for the performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

**Direct Comments to OMB:** Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, DC 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Dr. Carrie Klabunde, Epidemiologist, Division of Cancer Control and Population Sciences, National Cancer Institute, Executive Plaza North 4005, 6130 Executive Boulevard, Bethesda, Maryland 20892-7344 or call non-toll-free 301-402-3362 or E-mail your request, including your address, to: [klabundc@mail.nih.gov](mailto:klabundc@mail.nih.gov).

**Comments Due Date:** Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication.

Dated: April 4, 2006.

**Rachelle Ragland-Greene,**

*National Institutes of Health, NCI Project Clearance Liaison.*

[FR Doc. E6-5532 Filed 4-13-06; 8:45 am]

**BILLING CODE 4101-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice

is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Cancer Institute Special Emphasis Panel, Cancer Detection.

**Date:** May 5, 2006.

**Time:** 11 a.m. to 5 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute, 6116 Executive Boulevard, Room 8125, Bethesda, MD. (Telephone Conference Call).

**Contact Person:** Virginia P. Wray, PhD., Deputy Chief, Research Programs Review Branch, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8125, Bethesda, MD 20892-8328. 301/496-9236. [wrayv@mail.nih.gov](mailto:wrayv@mail.nih.gov).

**Name of Committee:** National Cancer Institute Special Emphasis Panel, Spore in Breast Cancer Review.

**Date:** May 16-18, 2006.

**Time:** 8 a.m. to 5 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Double Tree Rockville, 1750 Rockville Pike, Rockville, MD 20852.

**Contact Person:** Shamala K. Srinivas, PhD., Scientific Review Administrator, Grants Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 8133, Bethesda, MD 20892. 301/594-1224.

**Name of Committee:** National Cancer Institute Initial Review Group, Subcommittee F—Manpower & Training.

**Date:** June 13-14, 2006.

**Time:** 8 a.m. to 5 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Hilton Old Town Alexandria, 1767 King Street, Alexandria, VA 22314.

**Contact Person:** Lynn M. Amende, PhD., Scientific Review Administrator, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8105, Bethesda, MD 20892. 301-451-4759. [amendel@mail.nih.gov](mailto:amendel@mail.nih.gov).

**Name of Committee:** National Cancer Institute Special Emphasis Panel, Clinical Cluster Review.

**Date:** June 19-21, 2006.

**Time:** 6 p.m. to 6 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Boulevard, Gaithersburg, MD 20878.

**Contact Person:** Wlodek Lopaczynski, PhD., MD, Scientific Review Administrator, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8133, Bethesda, MD 20892. 301-594-1402. [lopacw@mail.nih.gov](mailto:lopacw@mail.nih.gov).

**Name of Committee:** National Cancer Institute Initial Review Group, Subcommittee A—Cancer Centers.

**Date:** August 3-4, 2006.

**Time:** 1 p.m. to 12 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Hyatt Regency Bethesda, 7400 Wisconsin Avenue, Bethesda, MD 20814.

**Contact Person:** David E. Maslow, PhD., Scientific Review Administrator, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8117, Bethesda, MD 20892-7405. (301) 496-2330. [dm65y@nih.gov](mailto:dm65y@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: April 6, 2006.

**Anna Snouffer,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 06-3568 Filed 4-13-06; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Human Genome Research Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council for Human Genome Research.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property